Adult
Conditions
Interventions
Placebo Intake: 0 mg Ingesion: 168 days
Propolis Intake: 542.88 mg Ingesion: 168 days
Sponsors
KSO Corporation
Research Center for Immunological Analysis. Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy Japanese men and women aged greater than or equal to 60 years, less than 80 years at the time of obtaining informed consent. 2. Subjects with MMSE score of 24 to 29 at screening. 3. Subjects who have subjective forgetfulness or have been pointed out forgetfulness by others. 4. Subjects who normally take three meals a day. 5. Subjects who got adequate explanation about the purpose and details of the examination, have the capacity to consent, voluntarily participate in understanding, and agree to participate in the examination in writing.
Exclusion criteria
Exclusion criteria: 1. Subjects who judged by a doctor as dementia. 2. Subjects who have taken or had taken drugs of dementia or drugs affecting cognitive function 3. Subjects who have current medical history or past medical history of mental disorders (including depressive symptoms) or cerebrovascular diseases. 4. Subjects who regularly use supplements or health foods that may affect cognitive functions. 5. Subjects who judged inappropriate as subjects as a result of clinical examination of screening 1 or brain MRI examination of screening 2. 6. Subjects who were extremely irregular in their lifestyle such as meals or sleeping. 7. Subjects who have a history of asthma or current medical history. 8. Subjects who have allergies to bee products (honey etc.), conifers, trees of Pinaceae, poplar and salicylic acid. 9. Subjects who have history of alcohol dependence or current medical history. 10. Subjects who consume a large amount of alcohol routinely 11. Subjects who have serious illness or medical history such as diabetes, liver disease, kidney disease, heart disease. 12. Subjects who have medical history or history of food allergies or current medical history. 13. Subjects who have take warfarin potassium 14. Subjects who have gerontological depression scale (GDS-S-J) score of 6 or more 15. Subjects who have color vision disorder and can not easily hear people's talk at short distance. 16. Subjects who have problems with the functions of both hands due to injury, surgery, etc. 17. Participating in other food intake, testing using medicines, applying cosmetics and medicines etc, person participating in other studies during participation in this study, consent acquisition within 1 month For other exams Participants 18. Others who judged that the investigator is inappropriate as the subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitrax (total score of verbal memory, visual memory, finger swing, SDC, stroop, attention shift, persistent processing and 4 part sustained processing) Measuring before intake and 24 weeks after intake. | — |
Secondary
| Measure | Time frame |
|---|---|
| MMSE, VAS on forgetfulness and markers related inflammation and heavy metal. Measuring before intake and 24 weeks after intake. | — |
Countries
Japan
Contacts
Public ContactYoshika Komori
KSO Corporation Sales department
Outcome results
None listed